Santhera Pharmaceuticals Holding 관리

관리 기준 확인 2/4

Santhera Pharmaceuticals Holding CEO는 Dario Eklund, Dec2019 에 임명되었습니다 의 임기는 4.92 년입니다. 총 연간 보상은 CHF 1.72M, 30.1% 로 구성됩니다. 30.1% 급여 및 69.9% 보너스(회사 주식 및 옵션 포함). 는 CHF 35.55K 가치에 해당하는 회사 주식의 0.037% 직접 소유합니다. 35.55K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 4.5 년입니다.

주요 정보

Dario Eklund

최고 경영자

CHF 1.7m

총 보상

CEO 급여 비율	30.1%
CEO 임기	4.9yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	4.5yrs

최근 관리 업데이트

Recent updates

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

Jun 26

CEO 보상 분석

Dario Eklund 의 보수는 Santhera Pharmaceuticals Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CHF 63m
Mar 31 2024	n/a	n/a	CHF 59m
Dec 31 2023	CHF 2m	CHF 516k	CHF 55m
Sep 30 2023	n/a	n/a	-CHF 5m
Jun 30 2023	n/a	n/a	-CHF 65m
Mar 31 2023	n/a	n/a	-CHF 68m
Dec 31 2022	CHF 2m	CHF 505k	-CHF 71m
Sep 30 2022	n/a	n/a	-CHF 68m
Jun 30 2022	n/a	n/a	-CHF 65m
Mar 31 2022	n/a	n/a	-CHF 60m
Dec 31 2021	CHF 1m	CHF 500k	-CHF 56m
Sep 30 2021	n/a	n/a	-CHF 56m
Jun 30 2021	n/a	n/a	-CHF 56m
Mar 31 2021	n/a	n/a	-CHF 62m
Dec 31 2020	CHF 681k	CHF 500k	-CHF 68m
Sep 30 2020	n/a	n/a	-CHF 46m
Jun 30 2020	n/a	n/a	-CHF 24m
Mar 31 2020	n/a	n/a	-CHF 21m
Dec 31 2019	CHF 2m	CHF 42k	-CHF 19m

보상 대 시장: Dario 의 총 보상 ($USD 1.94M )은 Swiss 시장( $USD 809.77K ).

보상과 수익: Dario 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dario Eklund (56 yo)

4.9yrs

테뉴어

CHF 1,715,974

보상

Mr. Dario Eklund has been Chief Executive Officer at Santhera Pharmaceuticals Holding AG since December 1, 2019. He served as Head of Global Business Operations at Vifor Pharma Ltd. since 2014.He served a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas Meier	Founder & Chairman	7.6yrs	CHF 200.00k	0.26% CHF 245.6k
Dario Eklund	Chief Executive Officer	4.9yrs	CHF 1.72m	0.037% CHF 35.5k
Andrew Smith	Chief Financial Officer	4.6yrs	데이터 없음	데이터 없음
Oliver Strub	Head of Compliance	less than a year	데이터 없음	데이터 없음
Günther Metz	Head Business Development	no data	데이터 없음	0.0083% CHF 7.9k
Shabir Hasham	Chief Medical Officer	no data	데이터 없음	0.022% CHF 20.9k
Marc Schrader	Chief Technology Officer	less than a year	데이터 없음	데이터 없음
Oliver Kronenberg	Chief Legal Officer & Corporate Secretary	less than a year	데이터 없음	데이터 없음
Neville Kodkani	Head of Global Marketing & Partner Management	no data	데이터 없음	데이터 없음
Sarah Holmes-Klotz	Head of People & Culture	2.7yrs	데이터 없음	데이터 없음
Andreas Missy	Executive Vice President of Corporate Planning & Business Development	no data	데이터 없음	데이터 없음
Geert van Daal	Chief Commercial Officer	no data	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: SANN 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Meier	Founder & Chairman	7.6yrs	CHF 200.00k	0.26% CHF 245.6k
Otto Schwarz	Director	1.4yrs	CHF 143.75k	데이터 없음
Bradley Meyer	Director	1.4yrs	CHF 168.75k	0.026% CHF 24.4k
Philipp Gutzwiller	Non Executive Independent Director	7.6yrs	CHF 145.00k	0.11% CHF 106.6k

4.5yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: SANN 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.

Santhera Pharmaceuticals Holding 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Santhera Pharmaceuticals Holding AG Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary of Santhera Pharmaceuticals AG, Effective August 1, 2024

Santhera Pharmaceuticals Holding AG, Annual General Meeting, May 28, 2024

Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Apr 26, 2023

Insufficient new directors

Santhera Pharmaceuticals Holding AG Announces Board Changes

Recent updates

Santhera Pharmaceuticals Announces Positive Topline Results from LIONHEART Study with AGAMREE®? (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism

First half 2024 earnings released: CHF1.35 loss per share (vs CHF2.09 loss in 1H 2023)

Santhera Pharmaceuticals Holding AG to Report First Half, 2024 Results on Sep 12, 2024

Santhera Pharmaceuticals Holding AG Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary of Santhera Pharmaceuticals AG, Effective August 1, 2024

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

New minor risk - Market cap size

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on May 31, 2024

Third quarter 2023 earnings released

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA

New minor risk - Financial data availability

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Santhera Pharmaceuticals Holding AG, Annual General Meeting, May 28, 2024

New major risk - Financial position

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Santhera Pharmaceuticals Holding AG Launches AGAMREE (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer

Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Market cap size

First half 2023 earnings released: CHF2.09 loss per share (vs CHF5.24 loss in 1H 2022)

Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG (SWX:SANN).

Santhera Pharmaceuticals Holding AG to Report First Half, 2023 Results on Sep 07, 2023

Forecast breakeven date moved forward to 2023

Santhera Pharmaceuticals Holding AG announced that it expects to receive $14.999996 million in funding from Catalyst

Full year 2022 earnings released

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Apr 26, 2023

Santhera and Reveragen Announces FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

European Medicines Agency Validates Santhera Pharmaceuticals Holding AG’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

First half 2022 earnings released: CHF0.52 loss per share (vs CHF0.92 loss in 1H 2021)

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG to Report First Half, 2022 Results on Oct 31, 2022

Forecast to breakeven in 2024

Santhera Pharmaceuticals Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Santhera Pharmaceuticals Holding AG Announces Board Changes

Santhera Pharmaceuticals Holding AG Updates on Ongoing NDA Submission for Vamorolone

Santhera Pharmaceuticals Holding AG Announces that Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Jun 29, 2022

Insufficient new directors

Santhera Pharmaceuticals Holding AG Appoints Shabir Hasham as Chief Medical Officer and a Member of Santhera’s Executive Management Team, Effective May 1, 2022

Santhera Pharmaceuticals and Reveragen Biopharma, Inc Announces Initiation of Rolling New Drug Application Submission to U.S. Food and Drug Administration

Price target increased to CHF7.00

Forecast to breakeven in 2024

Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in funding from Highbridge Capital Management, LLC

Price target decreased to CHF4.75

First half 2021 earnings released: CHF0.92 loss per share (vs CHF2.78 loss in 1H 2020)

Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 35 million in funding from Idorsia Pharmaceuticals Ltd., Highbridge Capital Management, LLC, Waypoint Capital and other investors

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference

Santhera Pharmaceuticals Holding AG Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy

Consensus revenue estimates increase to CHF16.8m

Price target increased to CHF6.23

Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study

Executive VP, Chief Medical Officer & Head of Development has left the company

Santhera Pharmaceuticals and ReveraGen Biopharma Announce New 2.5-Year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2020 Final Results on Apr 27, 2021

New 90-day high: CHF3.20

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Departure of Kristina Sjöblom Nygren, Chief Medical Officer and Head of Development

New 90-day low: CHF3.29

Analysts increase EPS estimates to -CHF3.25

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone